Catalogo Ricerca

Catalogo Ricerca: [31796] Home page macrotipologia

Sfoglia

1 Contributo su Rivista 28553
- 1.1 Articolo in rivista 24941
- 1.2 Recensione in rivista 910
- 1.3 Scheda bibliografica 0
- 1.4 Nota a sentenza 71
- 1.5 Abstract in rivista 2015
- 1.6 Traduzione in rivista 0
- 1.7 Lettera 283
- 1.8 Materiale editoriale 333

2 Contributo in Volume 1060

3 Libro 80

4 Contributo in Atti di Convegno (Proceeding) 1910
- 4.1 Contributo in Atti di convegno 735
- 4.2 Abstract in Atti di convegno 990
- 4.3 Poster 185

5 Altro 57
- 5.01 Composizione 0
- 5.02 Disegno 0
- 5.03 Design 0
- 5.04 Performance 0
- 5.05 Esposizione 0
- 5.06 Mostra 0
- 5.07 Manufatto 0
- 5.08 Prototipo d'arte e relativi progetti 0
- 5.09 Cartografia 0
- 5.10 Banca dati 5
- 5.11 Software 0
- 5.12 Altro 52
- 5.13 Progetto architettonico 0

6 Brevetti 42
- 6.1 Brevetto 42

7 Curatele 0
- 7.1 Curatela 0

8 Tesi di dottorato 94
- 8.1 Tesi di dottorato 94

Prodotti recenti

Ciliogenesis in Pancreatic Neuroendocrine Tumors: Insight into the Role of WDR60

: Primary cilia have emerged as key regulators in cancer biology, influencing tumor progression and therapeutic response through diverse signaling pathways. In this study, we identify WDR60, a component of the dynein-2 complex essential for retrograde intraflagellar transport, as a novel modulator of pancreatic neuroendocrine tumor (Pa-NET) behavior. Transcriptomic analysis of the GEO dataset GSE73338 revealed that WDR60 is significantly upregulated in both primary and metastatic Pa-NETs comp...

Neoadjuvant chemotherapy followed by interval surgery versus primary debulking surgery in FIGO stage III-IV epithelial ovarian cancer: A systematic review and meta-analysis

Objective: To compare survival and perioperative outcomes of Primary debulking surgery (PDS) versus neoadjuvant chemotherapy followed by interval debulking surgery (NACT-IDS) in newly diagnosed FIGO stage III-IV ovarian cancer. Primary outcomes were overall survival (OS) and progression-free survival (PFS). Data sources: MEDLINE, Embase, CENTRAL, Web of Science, Scopus, Cochrane Library, major conference proceedings (inception to July 13, 2025) STUDY SELECTION: Phase-III randomized trials com...

Durvalumab in Advanced Biliary Tract Cancer: Real‐World Data From a Large Cohort of Patients Across Multiple International Centers

Background: We recently published the first real-world multicenter and multi-institutional study of cisplatin, gemcitabine, and durvalumab in patients with advanced biliary tract cancer (BTC). Here we present an expanded patient cohort with an increased sample size and longer median follow-up. Methods: The study population included patients with advanced BTC, who received cisplatin/gemcitabine plus durvalumab at 55 centers across 12 countries in Europe, the United States, and Asia. The primar...

Genomic profiling in hepatocellular carcinoma: a real-world retrospective analysis

Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality, with limited molecular characterization due to reliance on radiological diagnosis. This study aims to characterize the genomic landscape of advanced HCC and assess the prognostic and predictive roles of genetic alterations (GAs). Patients and methods: This study used a de-identified nationwide (USA-based) HCC clinico-genomic database to retrospectively analyze patients with advanced HCC who received sys...

Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumab

Background Biliary tract cancers (BTC) are aggressive malignancies with limited therapeutic options. Recent advances have integrated immunotherapy into the standard of care, yet outcomes remain heterogeneous, emphasizing the need for molecular biomarkers to guide patient selection. This study aimed to assess the prognostic impact of pathway-level genomic alterations in patients with BTC treated with first-line cisplatin, gemcitabine, and durvalumab. Methods This retrospective, multicenter stu...

Scopri

Accesso al fulltext

no fulltext29415
reserved1469
open910
embargoed1
partially open1